Topics from this paper
In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
- The Journal of pharmacology and experimental therapeutics
T-794 was effective in three animal models of depression and had potency similar to or greater than moclobemide, tranylcypromine or imipramine and had a lack of the anticholinergic activity. Expand
Development and validation of an analytical procedure to detect spatio-temporal differences in antidepressant use through a wastewater-based approach.
- Medicine, Chemistry
A new bioanalytical method was developed, optimised and validated for the analysis of a broad range of antidepressants and their metabolites at trace concentrations in influent wastewater, and proved capable of analysing high resolution spatio-temporal trends. Expand
MAO-A Inhibitory Potential of Terpene Constituents from Ginger Rhizomes—A Bioactivity Guided Fractionation
- Chemistry, Medicine
Terpene constituents from ginger’s extract were found to exhibit moderate inhibitory properties against the MAO-A enzyme in in vitro tests. Expand
Effect of dichloromethane fraction of Areca catechu nut on monoamines associated behaviors and tyramine pressor sensitivity in rodents.
- Chemistry, Medicine
- Pakistan journal of pharmaceutical sciences
Results suggest that the dichloromethane fraction of A. catechu nut primarily elevates serotonin levels (probably via monoamine oxidase A inhibition) and does not induce cheese effect. Expand
The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders
- Expert opinion on therapeutic targets
The prospect of one such target, the corticotropin-releasing factor system, as having an enhanced therapeutic profile with the potential of a broader range of efficacy with reduced side effect liabilities is examined. Expand
New approaches to developing antidepressants by enhancing monoaminergic neurotransmission
- Expert opinion on investigational drugs
This review focuses on novel compounds in different stages of development for the treatment of MDD that enhance monoaminergic neurotransmission via a number of different mechanisms, including re-uptake inhibition of one or more monoamines, monoamine oxidase inhibitors, the combination of monoamine antagonists with re-ptake inhibitors and monoamine receptor subtype agonists. Expand
Effect of Nonnicotine Pharmacotherapy on Smoking Behavior
Drugs that modulate noradrenergic neurotransmission (bupropion, nortriptyline, moclobemide) are more effective than those affecting serotonin (selective serotonin reuptake inhibitors, buspirone, ondansetron) or other neurotransmitters. Expand
La depresión en el anciano.
La depresion es el problema psiquiatrico mas comun en el anciano1. Su presentacion es muchas veces atipica, por lo que se considera un reto ante el que se enfrenta todo medico que atiende a un… Expand
Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview
- Psychology, Medicine
- Canadian journal of psychiatry. Revue canadienne de psychiatrie
Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients and of similar efficacy to the TCAs and the more recently introduced SSRIs. Expand
Epidural anaesthesia, ephedrine and phenylephrine in a patient taking moclobemide, a new monoamine oxidase inhibitor
The short half‐life of moclobemide and its modest interaction with direct and indirect acting sympathomimetic drugs permit the use of epidural anaesthesia, since any associated hypotension can be safely treated. Expand